BRIEF published on 01/06/2025 at 18:05, 4 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Transparency Biopharmaceutical Shareholding Atlas Special Opportunities Oxurion
BRIEF published on 01/06/2025 at 18:05, 4 days ago Oxurion reçoit une notification de transparence de la part d'Atlas Special Opportunities LLC Actionnariat Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
PRESS RELEASE published on 01/06/2025 at 18:00, 4 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion NV received a transparency notification from Atlas Special Opportunities, LLC revealing a stake above 15% threshold due to purchase of voting securities Transparency Notification Biopharmaceutical Atlas Special Opportunities Ophthalmic Therapies Oxurion NV
PRESS RELEASE published on 01/06/2025 at 18:00, 4 days ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC Oxurion NV receives transparency notification from Atlas Special Opportunities LLC regarding ownership of 624,817 shares, exceeding the 15% threshold Transparency Notification Share Ownership Atlas Special Opportunities LLC Oxurion NV Ophthalmological Therapies
BRIEF published on 01/03/2025 at 18:05, 7 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Shares Transparency Biopharmaceutical Atlas Special Opportunities Oxurion
BRIEF published on 01/03/2025 at 18:05, 7 days ago Oxurion reçoit une notification de transparence de la part d'Atlas Special Opportunities LLC Actions Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
PRESS RELEASE published on 01/03/2025 at 18:00, 7 days ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion NV received a transparency notification under Belgian Transparency legislation from Atlas Special Opportunities, LLC, regarding the sale of voting securities Transparency Notification Atlas Special Opportunities LLC Oxurion NV Belgian Legislation Retinal Disease Therapy
PRESS RELEASE published on 01/03/2025 at 18:00, 7 days ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC Oxurion NV announces receipt of transparency notification regarding shareholding. Bio-pharmaceutical company developing ophthalmological therapies. Refer to website for more details Transparency Notification Shareholding Belgium Oxurion NV Ophthalmological Therapies
BRIEF published on 12/31/2024 at 18:05, 10 days ago Oxurion reporte une transaction stratégique en raison de discussions en cours Report Transaction Stratégique Oxurion Discussions Financières Louvain
BRIEF published on 12/31/2024 at 18:05, 10 days ago Oxurion Postpones Strategic Transaction Due to Ongoing Discussions Report Strategic Transaction Oxurion Leuven Financial Discussions
Published on 01/10/2025 at 18:15, 31 minutes ago The Melrose Group Files Motion for Default Judgment Against Hank & Uptempo's Michael A. Hilmer and Jason Ewart
Published on 01/10/2025 at 16:45, 2 hours 1 minute ago AML Incubator Launches Compliance Solution for European MSBs and VASPs Facing MiCA Regulatory Challenges
Published on 01/10/2025 at 15:00, 3 hours 46 minutes ago Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
Published on 01/10/2025 at 14:30, 4 hours 16 minutes ago Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week
Published on 01/10/2025 at 14:30, 4 hours 16 minutes ago Gryphon Digital Mining Signs Definitive Agreement for HPC/AI Asset Scalable to 4GW of Green Energy Through Natural Gas and Carbon Sequestration
Published on 01/10/2025 at 18:31, 14 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/10/2025 at 18:18, 27 minutes ago EQS-Adhoc: Ströer confirms discussions with interested parties regarding Ströer's core assets
Published on 01/10/2025 at 18:00, 46 minutes ago Invesco Digital Markets plc: Change to the Reduction Percentage of the Secured Bitcoin-Linked Certificates
Published on 01/10/2025 at 18:00, 46 minutes ago ACTIA Group : Calendrier des publications financières 2025
Published on 01/10/2025 at 17:45, 1 hour 1 minute ago LANSON-BCC : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ ENTRE LANSON-BCC ET NATIXIS ODDO BHF
Published on 01/10/2025 at 17:40, 1 hour 6 minutes ago Déclaration du nombre d'actions composant le capital et du nombre total de droits de vote au 31 décembre 2024
Published on 01/10/2025 at 17:40, 1 hour 6 minutes ago Disclosure of the number of shares and the total number of voting rights as of December 31, 2024
